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Abstract
Background: Evidence suggests that individuals with social anxiety demonstrate vigilance to social threat, whilst the peptide 
hormone oxytocin is widely accepted as supporting affiliative behaviour in humans.
Methods: This study investigated whether oxytocin can affect attentional bias in social anxiety. In a double-blind, randomized, 
placebo-controlled, within-group study design, 26 healthy and 16 highly socially anxious (HSA) male volunteers (within the 
HSA group, 10 were diagnosed with generalized social anxiety disorder) were administered 24 IU of oxytocin or placebo to 
investigate attentional processing in social anxiety. Attentional bias was assessed using the dot-probe paradigm with angry, 
fearful, happy and neutral face stimuli.
Results: In the baseline placebo condition, the HSA group showed greater attentional bias for emotional faces than healthy 
individuals. Oxytocin reduced the difference between HSA and non-socially anxious individuals in attentional bias for emotional 
faces. Moreover, it appeared to normalize attentional bias in HSA individuals to levels seen in the healthy population in the 
baseline condition. The biological mechanisms by which oxytocin may be exerting these effects are discussed.
Conclusions: These results, coupled with previous research, could indicate a potential therapeutic use of this hormone in 
treatment for social anxiety.
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Introduction
Research has indicated oxytocin as a key neuromodulator of 
social and emotional processing across phyla. Oxytocin has a 
long evolutionary lineage linked to social approach and recog-
nition behaviour (Lee et al., 2009). Moreover, oxytocin is widely 
accepted as supporting affiliative behaviour in humans by mod-
ulating emotional processing. Oxytocin has been shown to be 
centrally involved in the recognition and memory of facial iden-
tity (Savaskan et al., 2008; Rimmele et al., 2009) and also funda-
mental in the processing of facial emotion (Schulze et al., 2011), 
higher level mental states using cues from the eyes (Domes 
et  al., 2007), and social reward learning from emotional faces 
(Bethlehem et al., 2014; Clark-Elford et al., 2014).
At a neural level, oxytocin receptors are expressed in areas 
of the brain associated with emotion and attention, namely 
the amygdala (Huber et  al., 2005). In healthy volunteers, oxy-
tocin attenuates amygdala activity to threatening social stimuli 
(Kirsch et al., 2005). Oxytocin has also been shown to normal-
ize hyperactive amygdala response to threat-related cues and 
hyperactive medial prefrontal response to negative social cues, 
and to reduce amygdala-frontal resting-state functional connec-
tivity in patients with social anxiety disorder (SAD; Labuschagne 
et al., 2010, 2012; Dodhia et al., 2014). These findings demonstrate 
that oxytocin modulates a neural circuit known for social threat 
processing and emotion regulation, suggesting a neural mecha-
nism underlying oxytocin’s behavioral effects. Accordingly, in 
healthy volunteers behavioral findings suggest that oxytocin 
may have direct effects on social attention. Oxytocin has been 
shown to increase attention to the eye region (Guastella et al., 
2008)—although this is disputed (Domes et al., 2013)—increase 
attention toward emotional faces that shift gaze (Tollenaar 
et al., 2013), and increase vigilance to happy faces at early stages 
of attentional processing (Domes et al., 2013).
Maladaptive allocation of attention in socio-emotional pro-
cessing is also associated with clinical conditions such as anxi-
ety (Bar-Haim et al., 2007). According to Rapee and Heimberg’s 
(1997) influential model of social phobia, a bias to allocate atten-
tion—preferentially to social threat cues—may maintain the 
disorder, with enhanced threat processing exacerbating anxiety 
symptoms (Rapee and Heimberg, 1997). Several studies dem-
onstrate initial orientating and vigilance toward threat-related 
social stimuli in highly socially anxious (HSA) individuals (Mogg 
and Bradley, 2002; Mogg et  al., 2004; Gamble and Rapee, 2010; 
Staugaard, 2010). However, this bias is not invariably detected, 
and sometimes may operate for a wider range of emotional 
social cues, including happy faces (Staugaard, 2010). Attentional 
bias has potential therapeutic importance, as clinical trials indi-
cate that attention training interventions which reduce atten-
tion bias to social threat cues are effective in reducing social 
anxiety symptoms (Schmidt et al., 2009). Studies of the neural 
correlates of attentional bias to threat indicate that the bias 
occurs at early stages of information processing (Rossignol et al., 
2013) and is likely modulated by the amygdala (Carlson et al., 
2009). Coupled with evidence of hyperactivity of the amygdala to 
faces in patients with SAD (Yoon et al., 2007), which is reduced 
by oxytocin to similar activity levels as seen in healthy controls 
(Labuschagne et  al., 2010), this provides ground to investigate 
the effects of oxytocin on attentional bias to facial stimuli in 
social anxiety.
The primary aims of the current study were to investigate 
the effects of oxytocin on attentional bias in HSA individuals, 
using a dot-probe task. Considering prior theory (Rapee and 
Heimberg, 1997) and evidence of increased attention to threat 
faces in social anxiety (Mogg and Bradley, 2002; Mogg et  al., 
2004), we predicted that, at placebo baseline, HSA individuals 
would show greater attentional bias to threat faces compared 
to healthy controls (Hypothesis 1). Moreover, given findings that 
oxytocin attenuates hyperactivity of the amygdala to fear cues 
in HSA individuals (Labuschagne et  al., 2010), that the amyg-
dala mediates attention to fear cues in a dot-probe paradigm 
(Carlson et al., 2009), and that oxytocin increases attention to 
positive and negative emotional cues in healthy volunteers 
(Domes et  al., 2013; Tollenaar et  al., 2013), we also predicted 
that oxytocin would reduce the difference in attentional bias 
between the HSA and control groups for all emotional stimuli 
(Hypothesis 2).
Materials and Methods
Participants
Twenty-six controls, average age 26.00  years (standard devia-
tion  =  6.32, age range 18–42  years old) and 16 HSA partici-
pants, average age 27.13 (standard deviation = 9.25, age range 
19–51 years old) were included in the study. Of the 16 HSA par-
ticipants, 10 were diagnosed with generalized SAD by the study 
psychiatrists (see Procedure for details). All participants were 
recruited via the Internet and advertisements at the University 
of Cambridge and surrounding area.
Control participants were excluded from participation if 
they had any current or previous history of DSM IV–Axis I dis-
orders (as verified by the Mini International Neuropsychiatric 
Interview; Sheehan et al., 1998; administered by a psychiatrist), 
any other physical medical condition, history of alcohol or sub-
stance abuse (within 12 months of study entry), smoked, and/
or were currently prescribed medication known to affect brain 
function.
HSA participants were excluded if they were currently being 
prescribed medication, smoked, were suffering from a current 
depressive episode (evident ≤6  months) or alcohol/substance 
abuse (within 12 months of study entry), or another anxiety dis-
order (e.g. generalized anxiety disorder, specific phobia, or panic 
disorder) that was more clinically salient or preceded their social 
anxiety. Participants were also excluded if they had a history of 
obsessive-compulsive disorder, body dysmorphic disorder, post-
traumatic stress disorder, bipolar disorder, psychotic disorder, 
mental retardation, developmental disorder, or any other physi-
cal medical condition.
All participants provided written informed consent and 
the study was conducted in accordance with the UK National 
Research Ethics Committee (REC Reference: 10/H0308/77) 
and NHS Research and Development guidelines. This study 
was exempt from clinical trials status by the Medicines and 
Healthcare products Regulatory Agency.
Study Design
This study utilized a double-blind, randomized, placebo-con-
trolled, within-group study design whereby participants were 
tested under two acute treatment conditions separated by at 
least one week. Treatment conditions included an active intra-
nasal oxytocin spray (24IU, 40.32 micrograms, Syntocinon-spray, 
Novartis) and a placebo (containing all ingredients except for 
the peptide), both administered with three actuations to each 
nostril (4IU, 6.72 micrograms each). Oxytocin and placebo 
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administration were fully counterbalanced across both control 
and HSA groups.
Procedure
All participants attended a screening session followed by 
two nasal-spray study visits. Prior to or during screening ses-
sions all participants who presented as socially anxious were 
assessed using the Liebowitz Social Anxiety Scale (Liebowitz, 
1987). A  score of >70 (including >30 on the social situations 
subscale) was required to be included in the study as a HSA 
participant. Any participant who scored below these thresh-
olds was excluded, as in previous research (Dodhia et al., 2014). 
Those participants that reached criteria on the Liebowitz Social 
Anxiety Scale were then assessed using the Mini International 
Neuropsychiatric Interview (Sheehan et al., 1998) for diagnosis 
of generalized SAD at the screening session; however, a diag-
nosis of generalized SAD was not required to take part in the 
study. Finally, participants could not reach criteria for body dys-
morphic disorder as assessed by the Body Dysmorphic Disorder 
Questionnaire-Dermatology Version (Dufresne et al., 2001), veri-
fied by the study psychiatrist. Participants were also adminis-
tered the Beck Depression Inventory–II (Beck et  al., 1996) and 
the National Adult Reading Test (Nelson and Willison, 1991) at 
screening sessions. Control participants were assessed using 
the same measures and procedures; however, study psychia-
trists ensured that these participants did not suffer from any 
DSM IV–Axis I disorders and were fit for participation.
Prior to study visits all participants were asked to refrain from 
caffeine on the day of testing and alcohol was not permitted 
24 hours prior to the session. At study visits participants com-
pleted three pre-drug questionnaires: the Bond and Lader Visual 
Analogue Mood Scale (VAS; Bond and Lader, 1974), State-Trait 
Anxiety Inventory (STAI; Spielberg et al., 1983), and the Positive 
and Negative Affective Schedule (PANAS; Crawford and Henry, 
2004). The VAS consists of 16 visual analogue scales that assess 
current mood. Items were combined into three main scores: 
alertness, contentedness, and calmness. The PANAS is a 20 item 
self-report measure that assesses the extent to which a person 
feels positive affect or negative affect at that moment. The state 
and trait versions of the STAI measure how anxious the partici-
pant is feeling at that moment and in general, respectively, rated 
on a four-point Likert scale. Following a brief medical assess-
ment, nasal sprays were self-administered—supervised by a 
medical professional—and participants were then advised to 
rest for 45 minutes, consistent with previous studies (Bethlehem 
et al., 2013) and physiological evidence (Born et al., 2002). After 
this break, participants were again medically assessed and task 
administration began. Following cognitive testing, participants 
completed post-drug questionnaires (STAI, PANAS, and VAS) and 
asked whether they thought they received oxytocin or placebo 
at the session.
Experimental Task
The dot-probe task (MacLeod et al., 1986) is a well-established 
paradigm for measuring attentional bias. The current task was 
modeled on that used in previous research (Mogg and Bradley, 
2002; Mogg et  al., 2004). In brief, participants were presented 
with face pairs comprising emotional faces (angry, fearful, and 
happy) each paired with a neutral face of the same identity. 
Following the offset of the face pair a probe replaced the central 
location of a previously presented face. Participants responded, 
via button press, to the location of the probe stimulus (either left 
or right; see Figure 1).
Color photographs of 24 individuals were selected from the 
NimStim stimulus set (Tottenham et  al., 2009; contact Nim 
Tottenham at tott0006@tc.umn.edu for more information con-
cerning the stimulus set) to construct the face pairs for the emo-
tional conditions. In addition, a further 4 individuals were used 
to construct distractor face pairs, where two neutral expres-
sions of the same individual were paired. Each face pair was 
presented 8 times.
Each trial began with a fixation cross-followed by a face pair 
(emotion paired with a neutral face). Face stimuli were pre-
sented in color on a black background of approximately 55mm 
x 70mm, with a 75mm distance between them. After the face 
pair disappeared, a dot then appeared in the central location 
Figure 1. Illustration of trial events on dot-probe task, showing an angry-neutral face pair displayed prior to the probe, which on this trial replaces the neutral face 
(not drawn to scale).
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of one of the face stimuli, either congruent (same location as 
emotion face) or incongruent with the emotion face (same loca-
tion as the neutral face), and was displayed until button press 
response. Distance between dot-probe positions was 125mm. 
Participants then indicated the location of the probe (either on 
the left- or the right-hand side of the screen). A blank screen was 
then presented at randomly varying inter-trial intervals (500-
1250ms, averaging 1000ms). The task was fully counterbalanced 
for probe congruency to emotional faces and for probe location.
In total there were 16 practice trials (different stimuli, includ-
ing feedback on error trials), 224 experimental trials (presented 
in a new, random order for each participant; no feedback) and 
four buffer trials (two at the beginning of the experimental trials 
and two after a short mid-task break of one minute), for a total of 
244 trials, taking under 14 minutes to complete. The experiment 
was run on a Sahara Slate PC i400 Series using Presentation and 
a Cedrus RB-830 Response Pad was utilized for participants to 
indicate left or right.
Statistical Analysis
Median reaction times were calculated for each experimental 
condition as a function of emotional face type, face location, and 
probe location, as in previous studies (Browning et al., 2010). For 
each emotional face type, the attentional bias score is calculated 
by subtracting the median reaction times when the probe replaces 
the emotional face from the median reaction time when the 
probe replaces the neutral face. Positive values of an attentional 
bias score indicate that participants are quicker to respond to the 
probe that replaces an emotional face (vigilance to emotional face, 
relative to neutral face), and negative values indicate that partici-
pants are quicker to respond to probes that replace the neutral face 
(avoidance of emotional face, relative to neutral face). Bias scores 
were calculated for each condition: happy, fearful, and angry faces 
for both oxytocin and placebo sessions. Erroneous responses were 
excluded from analysis, comprising 1.2% of the data, and did not 
differ significantly across groups or study visits. Hypothesis 1 was 
evaluated using an independent t-test to compare groups on atten-
tional bias scores for threat (angry and fearful) faces averaged in 
the placebo baseline condition. To test Hypothesis 2, attentional 
bias scores were entered into a 2 group (HSA, control) x 2 drug 
(oxytocin, placebo) x 3 facial emotion (angry, fearful, happy) x 2 
drug order (oxytocin first, placebo first) mixed ANOVA. Drug order 
is entered as a between-subjects factor to account for learning and 
order effects. If interactions were significant, post-hoc compari-
sons were implemented and were corrected using an adjusted p 
value of .01 to account for multiple comparisons.
Groups were compared on age, National Adult Reading Test 
scores, and Beck Depression Inventory–II scores using independ-
ent t-tests. Subjective mood and anxiety (PANAS, VAS, and STAI) 
were assessed twice: pre- and post-drug administration. Separate 
analyses were conducted for PANAS positive and negative affect, 
each VAS score, and STAI state and trait anxiety scores. All study 
visit mood and anxiety questionnaires were analyzed using 2 
drug (oxytocin, placebo) x 2 group (HSA, control) x 2 time (pre, 
post) mixed ANOVAs. For all questionnaires, if main interactions 
were significant post-hoc pairwise comparisons were made and 
Bonferroni corrected for multiple comparison.
RESULTS
Demographics, Mood, and Anxiety Questionnaires
Groups did not significantly differ in age (p  =  .64) or IQ 
(p = .42). Compared with controls the HSA group demonstrated 
significantly greater trait (F[1,40]  =  20.13, p < .01) and state 
(F[1,40]  =  17.02, p < .01) anxiety across the sessions as meas-
ured by the STAI, and lower mood as demonstrated by the Beck 
Depression Inventory–II, t(40) = -3.89, p < .01. Moreover, oxytocin 
did not affect participants’ subjective ratings of mood or anxi-
ety. See Supplemental Materials S1 for more detail and means 
tables.
Attentional Bias Scores
Mean attentional bias scores for each condition are outlined in 
Table  1. To test Hypothesis 1 we used a planned independent 
t-test, which demonstrated that, post placebo, HSA participants 
showed increased attentional bias toward threat cues (averaged 
across angry and fearful faces) compared to controls (t[40] = 2.13, 
p =.04, d = .67, 2-tail uncorrected for hypothesis-driven test). The 
2 x 2 x 3 x 2 ANOVA of bias scores to test Hypothesis 2 revealed a 
significant group x drug interaction, which did not interact with 
type of facial emotion (F[1,38] = 10.58, p < .01, η2 = .22). There were 
no significant main effects of drug (p = .57), emotion (p = .62), or 
group (p =  .32). Furthermore, there was no main effect of drug 
order (p = .70) and were no interactions of drug order with any 
other variables. To clarify the group x drug interaction, post-hoc 
independent sample t-tests revealed that, in the placebo con-
dition, HSA participants demonstrate significantly increased 
attentional bias toward emotional faces in general (averaged 
across angry, fearful, and happy faces) compared to controls 
(t[40] = 2.63, p = .01, d = .83; see Figure 2, which illustrates this 
Table 1. Mean attentional bias scores for each condition.
Placebo Oxytocin
Mean S.D.  Mean S.D.
HSA Group Happy 3.23 14.11 -1.67 13.98
Fearful 3.50 14.48 4.02 15.70
Angry 5.83 10.09 -0.78 8.95
Control Group Happy -5.86 15.47 5.53 14.33
Fearful -1.14 8.61 2.91 11.82
Angry -0.63 12.56 -0.31 17.24
S.D., standard deviation; HSA, highly socially anxious 
Figure 2. Mean attentional bias scores for drug x group interaction. * indicates 
significant difference (p < .01); ns indicates non-significant.
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significant group difference in the placebo condition). However, 
following oxytocin there is no significant difference between 
the two groups in attentional bias scores for emotional faces 
(p  =  .41). Moreover, mean attentional bias scores of HSA par-
ticipants following oxytocin were not significantly different 
to bias scores of the control group following placebo (p =  .18). 
Furthermore, a paired-sample t-test revealed that attentional 
bias scores of the control group were significantly higher post-
oxytocin than post-placebo (p = .01, d = .59). In the HSA group, 
attentional bias scores tended to reduce post-oxytocin com-
pared with post-placebo, although this trend did not reach sig-
nificance (p = .10, d = .43; Figure 2).
Discussion
This study investigated the effects of oxytocin on attentional 
biases in highly socially anxious individuals and healthy con-
trols. At placebo baseline, HSA individuals demonstrate greater 
attentional bias toward threat cues, as well as toward emotion 
faces in general, compared to healthy controls. However, follow-
ing oxytocin administration the groups did not differ in their 
overall attentional bias to emotional faces. Indeed, following 
oxytocin HSA individuals demonstrated similar levels of atten-
tional bias to emotional faces as controls at placebo baseline, 
suggesting normalization of attentional bias.
Our results indicate that, at placebo baseline, social anxi-
ety was associated with significantly greater attentional bias to 
threat cues, consistent with previous research (Staugaard, 2010). 
The amygdala and prefrontal cortex modulate initial orientat-
ing of attention to threat-related stimuli in dot-probe paradigms 
(Carlson et  al., 2009) and dysfunction of this network could 
underlie clinical disorders, such as anxiety. Indeed, evidence 
suggests that limbic hyperactivity to social stimuli could indicate 
a biological marker for SAD (Yoon et al., 2007), and this hyper-
activity is hypothesised to drive attentional bias. Furthermore, 
areas including the prefrontal cortex have been shown to modu-
late attentional vigilance in a top-down fashion (Browning et al., 
2010). Moreover, anxiety is associated with reduced recruitment 
of the prefrontal cortex in top-down control over threat (Bishop 
et al., 2004). Therefore, increased initial attention toward emo-
tional stimuli coupled with difficulty in top-down modulation 
of attention in social anxiety could explain the observed atten-
tional bias to emotional faces.
An attentional bias in social anxiety for emotional faces is 
not frequently reported (Staugaard, 2010), in general, although 
some research suggests that social anxiety symptoms are asso-
ciated with increased attention towards both threat and happy 
faces (Bradley et al., 1999). Other evidence suggests that hyper-
activity of the amygdala in social anxiety generalizes across dif-
ferent types of emotional valence (Yoon et al., 2007). Given that 
under conditions of uncertainty HSA individuals show greater 
difficulty classifying emotion (Button et al., 2013) and recogniz-
ing happy faces (Silvia et  al., 2006), the experimental context 
may have contributed to this general emotional effect. Further 
research is needed to clarify the specific conditions under which 
attentional bias in social anxiety operates specifically for threat 
or for a more general range of emotional social cues.
This is the first study to suggest that oxytocin may have the 
potential to normalize attentional bias in HSA individuals, to 
levels seen in the healthy population. There is promising evi-
dence for the therapeutic effects of oxytocin in social anxiety 
(Guastella et al., 2009). Oxytocinergic pathways in the brain pro-
ject to several areas, specifically the emotion-regulating limbic 
system (McCarthy and Altemus, 1997) and amygdala (Huber 
et  al., 2005). Moreover, intranasal oxytocin administration 
has been shown to increase central amygdala oxytocin levels 
(Neumann et al., 2013). Therefore it is hypothesised that atten-
tional bias may be modulated by oxytocinergic increases in cen-
tral sites, including the amygdala, which facilitates subsequent 
connectivity with prefrontal regions in HSA participants. Indeed 
oxytocin has been shown to normalize hyperactive amygdala 
response to threat-related cues (Labuschagne et al., 2010) and 
hyperactive medial prefrontal response to negative social cues 
(Labuschagne et al., 2012), as well as to reduce amygdala-frontal 
resting-state functional connectivity (Dodhia et al., 2014) in SAD 
patients. The latter studies are consistent with our findings and 
suggest a neural basis for the normalization of attentional bias 
observed in this study.
Oxytocin supports a wide range of central systems, includ-
ing serotoninergic and dopaminergic function (Bethlehem et al., 
2013). Therefore it is likely that oxytocin is interacting with these 
systems to facilitate normalization of attentional bias, as seen 
in this study. For instance, serotonin manipulations have been 
shown to effect attentional bias (Merens et al., 2007). Moreover, 
oxytocin has indeed been shown to mediate central seroto-
nin production (Bethlehem et  al., 2013). Therefore oxytocin 
could be exerting behavioral effects through interactions with 
other key neurotransmitters. It is further questioned whether 
the behavioral effects of oxytocin are indeed due to oxytocin 
receptor interactions; for example, oxytocin has been shown 
to exert effects through interactions with arginine vasopressin 
V1a receptors (Bowen and McGregor, 2014). The role of oxytocin 
in mediating behavioral effects in humans is clearly complex, 
considering its supporting role in many neural systems. These 
interactions could mediate the effects of oxytocin on atten-
tional bias, as seen in the HSA group and typical volunteers in 
the current study.
It is noteworthy that in healthy controls, oxytocin increased 
attention to emotional faces. This is consistent with recent evi-
dence demonstrating that oxytocin can increase vigilance to 
positive cues (Domes et al., 2013) or emotional cues, in general, 
in healthy volunteers (Tollenaar et al., 2013), as well as induce 
pro-social effects (Kirsch et  al., 2005; Rimmele et  al., 2009). In 
the current sample the effect of oxytocin increasing attentional 
bias in controls was significant, whereas its effect of decreas-
ing attention bias in the HSA group was a trend that did not 
reach significance. This is likely a power issue and a methodo-
logical limitation of our study that warrants discussion. The 
sample for the HSA group was relatively small, although similar 
sample sizes have been used in previous studies (Mogg et al., 
2004). Furthermore, we do demonstrate medium to large effect 
sizes across the study and that the results are not due to any 
learning or order effects, further substantiating the results. The 
sample was also exclusively male, in common with most other 
research investigating effects of oxytocin (Bethlehem et  al., 
2013). Exclusively male samples prevent assessment of sex 
differences in oxytocinergic function in humans (Carter, 2007) 
and side effects associated with the use of intranasal oxytocin 
in females. This limits generalizability of the present results to 
female HSA individuals.
 A  strength of this study is that it examined the effect of 
oxytocin on attentional biases for different types of emotional 
stimuli. In addition to happy faces, fearful and angry expres-
sions were presented as they have previously been found to 
elicit consistent amygdala hyper-activation in SAD patients 
(Labuschagne et  al., 2010). Previous studies investigating the 
modulation of oxytocin on attentional bias have used differing 
combinations of happy, angry, fearful, or sad faces (Ellenbogen 
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et  al., 2012; Domes et  al., 2013). Researchers have noted that 
different negative expressions may elicit different action ten-
dencies resulting in oxytocinergic expression-specific effects: 
e.g. sad faces primarily elicit empathic responses, whilst happy 
faces elicit approach response tendencies (Putman et al., 2004; 
Tollenaar et al., 2013). This highlights the importance of further 
research elucidating the effects of oxytocin on attentional bias, 
depending on which emotional cues are presented.
The results of this study have potential relevance for a thera-
peutic use of oxytocin in individuals who experience high levels 
of persistent social anxiety. Indeed, oxytocin has been identified 
as a potential treatment for social anxiety disorder (Guastella 
et al., 2009); however, there is evidence that oxytocin detrimen-
tally affects people with borderline personality disorder (Bartz 
et  al., 2011), and administering oxytocin has been shown to 
hinder processing rewards from social stimuli in the healthy 
population (Clark-Elford et al., 2014). There is also evidence that 
chronic peripheral infusion of oxytocin causes a reduction in 
central oxytocin receptor binding in mice (Peters et  al., 2014). 
Further clinical trials are critically needed to assess the effects 
of oxytocin in such clinical conditions after consecutive doses 
and how this affects social functioning.
In conclusion, this is the first study to demonstrate that 
an acute administration of oxytocin reduces the difference 
between HSA and non-HSA individuals in attentional bias for 
emotional faces. We hypothesise that this effect is mediated 
by the modulatory effects of oxytocin on the amygdala–pre-
frontal cortex network, which supports emotion processing 
(Bethlehem et al., 2013). Further imaging and behavioral stud-
ies are required to assess the effects of repeated oxytocin 
administration on both social functioning and social informa-
tion processing, including attentional biases, in socially anx-
ious individuals.
Supplementary Material
For supplementary material accompanying this paper, visit 
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